VolitionRx Limited (NYSE American: VNRX) announced the submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study reported 97% specificity and identified 86% of lymphoma cases, marking a significant step toward commercializing a blood-based liquid biopsy test for feline cancer.
According to the company, the technology addresses a substantial unmet need in veterinary medicine. The test offers a non-invasive alternative to current diagnostic methods, which often require tissue biopsies or invasive procedures. The development also represents a commercial opportunity, with potential milestone payments and future revenue generation as Volition expands its presence in the growing companion animal oncology market.
The publication of the study in a peer-reviewed journal is expected to trigger a $5 million contractual milestone payment. This payment is tied to the achievement of specific development and regulatory milestones outlined in the company's agreements. The company noted that the study's strong results support the clinical utility of the Nu.Q Vet platform for early detection of feline lymphoma, a common cancer in cats that can be difficult to diagnose.
Volition is a multinational company focused on epigenetics, developing simple, cost-effective blood tests for early detection and monitoring of diseases, including some cancers and sepsis. The company's research and development activities are centered in Belgium, with an innovation lab and office in the U.S. and an office in London.
For more details, the full press release is available at https://ibn.fm/ARsEY. Additional information about Volition can be found on their website at www.Volition.com.
